TLSA logo

Tiziana Life Sciences Ltd

TLSA

Build a strategy around TLSA

Accountable AI Logo

Tiziana Life Sciences Ltd AI Insights

Informational only. Not investment advice.
As of 2026-02-09

Snapshot

  • Zero revenue TTM with 8.8M cash burn - 7.3M cash provides ~10 months runway before dilution[Cash and Equivalents]
  • P/B of 18.3x on 9.2M equity for pre-revenue biotech - priced for clinical success already[Price to Book Ratio]
  • R&D of 5.9M TTM is just 32% of opex - G&A heavy cost structure unusual for clinical-stage[Research and Development]

Watch Triggers

  • Cash and Equivalents: Falls below 5MTriggers emergency financing at distressed terms - severe dilution risk
  • Research and Development: Rises above 50% of Operating ExpenseWould signal shift to clinical execution over admin overhead
  • Total Revenue: Any revenue recognitionLicensing/milestone would validate pipeline and extend runway

Bull Case

168M market cap on 9.2M book value implies market pricing significant pipeline optionality - binary upside if trials succeed

Market CapCommon Stockholders Equity

Near-zero debt (0.01 D/E) preserves financing flexibility - can lever up or raise equity without covenant constraints

Debt to EquityTotal Debt

Bear Case

ROE of -232% and ROIC of -226% TTM - destroying capital at extreme rate with no revenue to offset

ROEROIC

R&D only 32% of opex (5.9M of 18.5M) - overhead-heavy structure suggests inefficient capital deployment

Research and DevelopmentOperating Expense

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
25%

Leverage TLSA's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Equity raise required within 12 months - dilution of 50%+ likely at current burn rate

3-12mhigh
  • 7.3M cash vs 8.8M annual burn = 10-month runway
  • 12M raised TTM via stock issuance shows pattern
  • No revenue pathway visible near-term
Cash 7.3M, FCF -8.8M TTMIssuance of Capital Stock 12M TTMTotal Revenue 0 TTM

Valuation Context

Caveats

Public Strategies Rankings

See how Tiziana Life Sciences Ltd ranks across different investment strategies.

Leverage TLSA's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.